Lifco AB (LIFCO-B) Fair Value & Analysis
Industrials · SE · Market cap 149B SEK
Fair value as of: Jul 18, 2026
From 24 valuation models · updated 3 days ago
Share price +4.3% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 272.44 – kr 379.04 · fair‑value band kr 109.29 – kr 182.15 · the kr 320.20 price screens above the kr 145.72 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lifco AB (LIFCO-B) currently trades at kr 320.20, while our model-based Fair Value estimate is kr 145.72, implying the stock looks roughly 54.5% overvalued today. We read business quality at 59/100 (solid quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Lifco AB generated revenue of 28.5B SEK at a net margin of 13.0%. Revenue grew 3.6% year over year. It earns a return on equity of 19.3%. Net debt stands at 9.1B SEK. Fundamentals as of Jul 18, 2026
Our scenario range runs from kr 109.29 (bear case) to kr 182.15 (bull case); at kr 320.20, the current price sits above that range. The share trades about 21% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -10% fair-value upside, at -54%, LIFCO-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Lifco AB (publ) engages in the dental, demolition and tools, and systems solutions businesses in Sweden, Norway, Finland, Germany, rest of Europe, the United Kingdom, Asia, Australia, Italy, North America, and internationally. It is involved in the distribution of dental equipment, such as denture attachments, disinfectants, saliva ejectors, bite registration and dental impression materials, bonding agents, and other consumables, as well as develops and sells medical record systems. The company also operates dental laboratory; and offers technical and software services. In addition, it develops, manufactures, and sells demolition robots, forest machines, crane and excavator attachments to heavy machine manufacturing, construction, forestry, nuclear, cement, and process industries. Further, the company offers machinery and equipment for electrical installations and electricity production, electrical equipment, equipment for recycling of various materials, and interiors for service …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lifco AB reported revenue of kr 28.3B in FY2025 versus kr 17.5B in FY2021, a compound +12.8%/yr. Reported net income was kr 3.6B in FY2025, compounding +11.0%/yr from FY2021.
Is LIFCO-B fairly valued? → Check now
Similar stocks
10 more Conglomerates stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Honeywell International Inc HON | 3,736 MXN | 2,515 MXN | -33% |
| CITIC Limited 0267 | HK$12.16 | HK$11.20 | -8% |
| Swire Pacific Limited 0019 | HK$81.70 | HK$13.77 | -83% |
| CK Hutchison Holdings 0001 | HK$68.50 | HK$141.53 | +107% |
| SK Inc 034730 | 625,000 KRW | 390,279 KRW | -38% |
| PT Astra International Tbk, ASII | 4,730 IDR | 16,231 IDR | +243% |
| Grupo Carso, S.A. GCARSOA1 | 130.55 MXN | 72.45 MXN | -45% |
| The Siam Cement Public Company SCC | 234.00 THB | 209.79 THB | -10% |
| SRF Limited SRF | ₹2,705 | ₹725.09 | -73% |
| Empresas Copec S.A COPEC | 5,980 CLP | 10,697 CLP | +79% |
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is Lifco AB (LIFCO-B) undervalued?
What is the fair value of LIFCO-B?
What is the quality score of LIFCO-B?
What is the revenue of Lifco AB (LIFCO-B)?
What is the net profit margin of LIFCO-B?
Does Lifco AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Lifco AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.